StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Sign in to jot down a private note about JUNS. Only you ever see it.
External sites have their own terms, paywalls, and accuracy standards. Stonvex doesn't endorse the content there.
Three bull points, three bear points, and one “what would change my mind” line — both sides forced onto one screen as a research note rather than a tip sheet.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-14 | $0.34 | $0.35 | +2.79% | 0.1M |
| 05-15 | $0.34 | $0.34 | -0.59% | 0.0M |
| 05-18 | $0.35 | $0.33 | -5.06% | 0.1M |
| 05-19 | $0.34 | $0.32 | -5.88% | 0.1M |
| 05-20 | $0.51 | $0.20 | -60.06% | 232.4M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Aggregate of 7 sell-side ratings as of 2026-05-01. Stonvex does not endorse these ratings.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Each factor shows JUNS's percentile within the scored universe — observational ranking, not a recommendation.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q1 2025 2025-03-31 | Annual 2024 2024-12-31 |
|---|---|---|---|---|
Revenue | $18.65K | $21.80K | $0.00 | $0.00 |
Operating Income | $-1.96M | $-8.91M | $-1.54M | $-3.09M |
Net Income | $-2.06M | $-8.64M | $-1.53M | $-2.44M |
EPS (Diluted) | $-0.06 | $-0.25 | $-0.05 | $-0.08 |
Total Assets | $3.95M | $5.56M | $4.96M | $6.20M |
Total Liabilities | $6.73M | $7.40M | $1.90M | $2.03M |
Cash & Equivalents | $2.36M | $3.79M | $2.71M | $3.77M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 36.28M | 34.45M | 33.10M | 33.10M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.